OpelzG.; Collaborative transplant study: 10 year report.Transplant Proc1992; 24: 2342–55.
3.
FirstM.R.. Renal allograft survival after 1 and 10 years: comparison between precyclosporin and cyclosporin data.Nephrol Dial Transplant1993; 9: 90–97.
4.
MehlsO., RigdenS., EhrichJ.H.. Report on management of renal failure in Europe, XXV, 1994 the child-adult interface.Nephrol Dial Transplant1996; 11(suppl. 1): S22–S36.
5.
TesiR.J., ErkhammasE.A., DaviesE.A.. Renal transplantation in older people.Lancet1994; 343: 461–64.
6.
CantarovichD., BaakrdR., BorangerT.. Cadaveric renal transplantation after 60 years of age: a single centre experience.Transpl Int1994; 7: 33–38.
7.
CanafaxD.M., MinD.I., GruberS.A.. Immunosuppression for cadaveric renal allograft recipients: a risk-factor, matched comparison of the Minnesota Randomized Trial with an antilymphoblast globulin, azathioprine, cyclosporine, and prednisone protocol.Clinical Transplantation1989; 3: 110–119.
8.
PerssonH., AnderssonC., LundgrenC.. Improved renal graft function in triple-drug treatment with low-dose cyclosporine.Transplant Proc1987; 19: 3586–8.
StefoniS., Nanni CostaA., BuscaroliA.. Validity of flow cytometry for cross-match evaluation in clinical renal transplantation.Nephron1991; 57: 268.
11.
StromT.B., TilneyN.L.. Immunobiology and immunopharmacology of graft rejection. In: SchrierR.W., GottschalkC.W., eds. Diseases of the kidney.Boston: Little Brown Company1993; 2879–910.
12.
KreisH.. Antilymphocyte globulins in kidney transplantation.Kidney Int Suppl1992; 38: S188–92.
13.
ThomsonA.W., StarzlT.E.. New immunosuppressive drugs: mechanicistic insight and potential therapeutic advances.Immunol Rev1993; 136: 71–98.
14.
MorrisR.E.. Immunopharmacology of new xenobiotic immunosuppressive molecules.Sem Nephr1992; 12: 306.
15.
AndersonW.F.. Human gene therapy.Science1992; 256: 808.